ISSN: 0340-7004

Journal Home

Journal Guideline

Cancer Immunology, Immunotherapy Q1 Unclaimed

Springer Science and Business Media Deutschland GmbH Germany

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Immunology, Immunotherapy is a journal indexed in SJR in Medicine (miscellaneous) and Immunology with an H index of 121. It has a price of 3190 €. It has an SJR impact factor of 1.723 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1.723.

Cancer Immunology, Immunotherapy focuses its scope in these topics and keywords: cells, cell, t, cancer, immune, human, cd, responses, tumor, suppressor, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Immunology (Q1) Immunology and Allergy (Q1) Immunology and Allergy (Q1) Medicine (miscellaneous) (Q1) Oncology (Q1)

Price

3190 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1.723

SJR Impact factor

121

H Index

360

Total Docs (Last Year)

579

Total Docs (3 years)

14754

Total Refs

3970

Total Cites (3 years)

556

Citable Docs (3 years)

6.93

Cites/Doc (2 years)

40.98

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Journal of Clinical Oncology Q1
Annals of Oncology Q1
Annual Review of Public Health Q1
The Lancet Global Health Q1
Nature Reviews Disease Primers Q1

Compare this journals

Aims and Scope

Best articles by citations

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-a2a and interleukin-2

The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies

Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine

Immunological inhibition of carcinogenesis

Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours

Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer

Modulation of costimulation to enhance tumor immunity

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

The effect of ranitidine on cellular immunity in patients with multiple myeloma

The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2

Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells

Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis

SHOW MORE ARTICLES

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

Production of a human monoclonal antibody recognising a determinant on mouse IgG2b from a patient receiving mouse monoclonal antibody for diagnostic imaging

Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors

Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation a

Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-a-treated chronic myelogenous leukaemia patients

Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons

Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association

Two-dimensional gel analysis of polypeptides from normal, preneoplastic and neoplastic mouse mammary tissues

The effects of ?GalCer-induced TCRV?24'V?11+ natural killer T cells on NK cell cytotoxicity in umbilical cord blood

Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide

Tumour escape: antitumour effectors too much of a good thing?